NCT06759948 (KY2024-853) is a Phase 1 clinical trial of GC012F injection in Generalized Myasthenia Gravis (gMG), sponsored by Chongbo Zhao.

Who is sponsoring NCT06759948?

NCT06759948 is sponsored by Chongbo Zhao.

What drugs are being tested in NCT06759948?

Interventions in NCT06759948: GC012F injection.

What condition does NCT06759948 study?

NCT06759948 studies Generalized Myasthenia Gravis (gMG).

Is NCT06759948 still recruiting?

NCT06759948 is currently not yet recruiting. Last updated 6 January 2025.

Last reviewed 2025-01-06 · How we verify

NCT06759948: KY2024-853

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not yet recruiting Phase 1 Last updated 6 January 2025

What this trial tests

Phase 1 trial testing GC012F injection in Generalized Myasthenia Gravis (gMG) in 18 participants. Not yet recruiting.

Timeline

15 February 2025

Primary endpoint
13 February 2027

10 September 2027

Quick facts

Lead sponsor	Chongbo Zhao
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	15 February 2025
Primary completion	13 February 2027
Estimated completion	10 September 2027
Sites	1 location across China

Drugs / interventions tested

GC012F injection — full drug profile →

Conditions studied

Generalized Myasthenia Gravis (gMG) — all drugs for Generalized Myasthenia Gravis (gMG) →

Sponsor

Chongbo Zhao

Who can join

Adults 18 to 75, any sex, with Generalized Myasthenia Gravis (gMG). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.
Jiang M, Zhao J, Yuan J, Yu Z, et al · · 2025 · cited 2× · PMID 40747591 · DOI 10.1080/21645515.2025.2538350
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Neurological implications of chimeric antigen receptor-T cell therapy.
Raffoul DG, Roos I, Mulazzani M, Anderson MA, et al · · 2026 · PMID 41877734 · DOI 10.1136/bmjno-2025-001491

Verify or expand the search:

Other trials of GC012F injection

Trials testing the same drug.

NCT07072884 — GC012F in Patients With Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07058298 — GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) · EARLY_PHASE1 · recruiting
NCT06419166 — An Exploratory Clinical Study of GC012F Injection for Refractory gMG · EARLY_PHASE1 · withdrawn
NCT05846347 — Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus · Phase 1 · unknown
NCT05858684 — Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients · EARLY_PHASE1 · unknown

Other recruiting trials for Generalized Myasthenia Gravis (gMG)

Currently open trials in the same condition.

NCT07215949 — Zilucoplan for Severe gMG Exacerbations · Phase 3 · recruiting
NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
NCT07058298 — GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06759948 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongbo Zhao
Last refreshed: 6 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06759948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing